ライフサイエンスコーパス: NTCP

1 NTCP and OATPs contribute to hepatic uptake of conjugate

2 NTCP could promote HBV RNA transcription, protein expres

3 NTCP from normal human liver (NHL) was first characteriz

4 NTCP inhibition using myrcludex B had only moderate effe

5 NTCP is also a target of multiple drugs.

6 NTCP predicts the choice made as a stochastic choice: Th

7 NTCP protein expression in HepG2/NTCP cells, despite bei

8 NTCP-expressing cell lines can be efficiently infected w

9 differ significantly from the predicted 8.8% NTCP (based on dose delivered) and excluded a 25% true i

10 Our results suggest that an NTCP model can be used prospectively to safely deliver f

11 We used an NTCP model with parameters calculated from our previous

12 sion was induced in hypercholanemic OATP and NTCP knockout mice, as well as in myrcludex B-treated ch

13 Expression of OATP and NTCP messenger RNA and protein was determined from a ban

14 bject variability in expression of OATPs and NTCP.

15 overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter import

16 Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated

17 In conclusion, NTCP appeared inefficient to mediate infection by serum-

18 gh-affinity Na+ /taurocholate cotransporter (NTCP) and the BA synthesizing enzyme cholesterol 7 alpha

19 No primary defects in the deduced NTCP amino acid sequence were found.

20 lc10a1-knockout mouse model (Slc10a1 encodes NTCP).

21 HepG2/NTCP cells released more viral antigens than HepG2 cells

22 NTCP protein expression in HepG2/NTCP cells, despite being driven by the cytomegalovirus

23 more efficient in HepaRG cells than in HepG2/NTCP cells.

24 ow HBsAg/HBeAg ratio by ccHBV-infected HepG2/NTCP cells was attributable to dimethyl sulfoxide (DMSO)

25 Moreover, HepG2/NTCP cells secreted very little hepatitis B surface anti

26 sed PM-PKC and decreased PM-MRP2 in both HuH-NTCP cells and hepatocytes.

27 AMP, increased MARCKS phosphorylation in HuH-NTCP cells and hepatocytes.

28 ed to increase MARCKS phosphorylation in HuH-NTCP cells transfected with DN-PKC, and this suggested P

29 In HuH-NTCP cells transfected with phosphorylation-deficient MA

30 In HuH-NTCP cells, dominant-negative (DN) PKC reversed TLC-indu

31 solic pMARCKS and decreased PM-MARCKS in HuH-NTCP cells.

32 taurocholate cotransporting polypeptide (HuH-NTCP cells) and in rat hepatocytes.

33 Human NTCP is a specific receptor for HBV and HDV.

34 Human NTCP plays an important role in the entry of hepatitis B

35 identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and

36 otide primers specific for rat ntcp or human NTCP transcripts revealed only the presence of the rat n

37 d that the clinical phenotype of a defect in NTCP might be hypercholanemia in the relative absence of

38 is known regarding genetic heterogeneity in NTCP.

39 ates functionally important polymorphisms in NTCP exist and that the likelihood of being carriers of

40 multiple single nucleotide polymorphisms in NTCP in populations of European, African, Chinese, and H

41 , ISG20 and tetherin, restrict HBV spread in NTCP-expressing hepatoma cells.

42 DNA, while dimethyl sulfoxide could increase NTCP protein level despite transcriptional control by a

43 may mediate choleretic effects by inserting NTCP into the plasma membrane, and nPKCepsilon may media

44 whereas the predominant uptake in humans is NTCP mediated.

45 n blotting of RNA from NHL revealed a 1.8-kb NTCP transcript.

46 new radiobiologic model to compute the liver NTCP from the microscale dose distribution.

47 dimethyl sulfoxide (DMSO) in culture medium, NTCP overexpression, and HBV genotype D.

48 In a subset of mice, NTCP deficiency resulted in markedly elevated total seru

49 Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-ty

50 d BSEP and MDR3 in parallel to a decrease of NTCP and CYP8B1 and an increase of MRP4.

51 o-associated virus, and stable expression of NTCP in a ccHBV producing cell line increased viral mRNA

52 s study revealed several unusual features of NTCP as an HBV receptor and established conditions for e

53 The receptor functions of NTCP and virus entry are blocked, in vitro and in vivo,

54 We describe the identification of NTCP deficiency as a new inborn error of metabolism with

55 The identification of NTCP deficiency confirms that this transporter is the ma

56 s an HBV receptor enabled ccHBV infection of NTCP reconstituted HepG2 cells, although very little hep

57 lts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or

58 Up-regulation of NTCP and CYP7A1 indicate failure to activate small heter

59 duct obstruction leads to down-regulation of NTCP mRNA levels, similar to that observed in rat common

60 xposure prevented SHP-mediated repression of NTCP and Cyp7A1 expression, which lead to increased BA s

61 out mouse model supports the central role of NTCP in hepatic uptake of conjugated BAs and hepatitis B

62 a bile acid levels are normal in a subset of NTCP knockout mice and in mice treated with myrcludex B,

63 5 and 126 micromol/L) in these two patients, NTCP messenger RNA (mRNA) and protein expression were qu

64 ent taurocholate cotransporting polypeptide (NTCP) allelic variants were also assessed.

65 ium taurocholate cotransporting polypeptide (NTCP) and impaired its bile acid transport activity.

66 Na+-taurocholate cotransporting polypeptide (NTCP) and multidrug resistance-associated protein 2 (MRP

67 ium taurocholate cotransporting polypeptide (NTCP) as an HBV receptor enabled ccHBV infection of NTCP

68 ium taurocholate cotransporting polypeptide (NTCP) as the hepatitis B virus (HBV) receptor enabled re

69 dent taurocholic cotransporting polypeptide (NTCP) expression and activity, multidrug resistance-asso

70 ium taurocholate cotransporting polypeptide (NTCP) has recently been reported to be an essential host

71 ium-taurocholate cotransporting polypeptide (NTCP) indicate a Na(+) -dependent bile acid uptake mecha

72 +) -taurocholate cotransporting polypeptide (NTCP) mediates uptake of conjugated bile acids (BAs) and

73 (+)/taurocholate cotransporting polypeptide (NTCP), OATP1, OATP2, ABCG5, and ABCG8) in the liver.

74 Na+-taurocholate cotransporting polypeptide (NTCP), responsible for bile acid (BA) uptake into hepato

75 ium taurocholate cotransporting polypeptide (NTCP), the currently accepted HBV receptor.

76 ium-taurocholate cotransporting polypeptide (NTCP), which is a hepatocellular transporter for bile ac

77 ium taurocholate cotransporting polypeptide (NTCP, encoded by SLC10A1), the recently identified bona

78 Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1).

79 +) -taurocholate cotransporting polypeptide (NTCP/SLC10A1) is believed to be pivotal for hepatic upta

80 ium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.

81 +)-taurocholate co-transporting polypeptide (NTCP; also known as SLC10A1) expressed in hepatocytes, a

82 ther metabolic pathways, as well as possible NTCP-related viral-drug interactions.

83 50% normal-tissue complication probability (NTCP) after lobar irradiation of the liver results in hi

84 lop a neuronal theory of the choice process (NTCP), which takes a subject from the moment in which tw

85 e Na(+)-taurocholate cotransporting protein (NTCP).

86 le salts are not sufficient to down-regulate NTCP expression, these two patients have abnormal respon

87 Thus, PKCs, by regulating NTCP trafficking, may also play an important role in hep

88 Remarkably, NTCP*2, a variant known to have a near complete loss of

89 d uptake and fluorescent labeling of several NTCP variants indicated that the sensor can also be used

90 ocholate cotransporting polypeptide SLC10A1 (NTCP) plays a key role in this process as the major tran

91 in mice treated with myrcludex B, a specific NTCP inhibitor.

92 Hepatic steady-state NTCP mRNA levels in a group of 23 pre- and postportoente

93 rus entry, is assumed to specifically target NTCP.

94 eports that identify new compounds targeting NTCP and inhibiting HBV entry.

95 ded in patients treated with drugs targeting NTCP.

96 IL-17A, IL-17F, TGF-beta1, alpha-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10,

97 patients have a defect in a gene other than NTCP that influences hepatic clearance of bile salts.

98 comparative expression arrays confirmed that NTCP, which was previously identified through a biochemi

99 oxyterminal antipeptide antibody showed that NTCP is a 39-kd polypeptide that is N-glycosylated to a

100 Human hepatocyte studies suggested that NTCP alone accounted for approximately 35% of rosuvastat

101 The NTCP obtained is in agreement with the data reported fro

102 Accordingly, the coding region of the NTCP gene of two children with this phenotype was sequen

103 analysis of NHL sections indicated that the NTCP protein is expressed on the basolateral surface of

104 virus preS1/Myrcludex B binding in vivo; the NTCP-independent hepatic BA uptake machinery maintains a

105 Consistent with this NTCP targeting, antiviral activity of vanitaracin A was

106 culture-derived HBV, which was attributed to NTCP overexpression, genotype D virus, and dimethyl sulf

107 Binding of HBV to NTCP limits its function, thus promoting compensatory BA

108 r human hepatic bile acid uptake transporter NTCP, but not rat Ntcp, also transported rosuvastatin.

109 uman sodium-dependent bile acid transporter (NTCP) permits analysis of its expression in human liver

110 Adiponectin correlated with NTCP and affects Cyp7A1 expression both in vivo and in v

111 ound was suggested to directly interact with NTCP and inhibit its transporter activity.

112 Here we present the first patient with NTCP deficiency, who was clinically characterized by mil